Interim results are in line with expectations, with a first significant contribution from US sales of Silhouette Instalift™. Top line growth of +6% YoY in constant currency is expected to accelerate in H2, and the Group continues to target EBITDA profitability for the full year. We reiterate Buy.
19 Sep 2017
N+1 Singer - Sinclair Pharma - H1’s in line; growth expected to accelerate in H2
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Sinclair Pharma - H1’s in line; growth expected to accelerate in H2
Sinclair Pharma (SPH:LON) | 0 0 0.6% | Mkt Cap: 111.5m
- Published:
19 Sep 2017 -
Author:
Dr Jens Lindqvist -
Pages:
3
Interim results are in line with expectations, with a first significant contribution from US sales of Silhouette Instalift™. Top line growth of +6% YoY in constant currency is expected to accelerate in H2, and the Group continues to target EBITDA profitability for the full year. We reiterate Buy.